These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27599564)

  • 1. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
    Prodosmo A; Buffone A; Mattioni M; Barnabei A; Persichetti A; De Leo A; Appetecchia M; Nicolussi A; Coppa A; Sciacchitano S; Giordano C; Pinnarò P; Sanguineti G; Strigari L; Alessandrini G; Facciolo F; Cosimelli M; Grazi GL; Corrado G; Vizza E; Giannini G; Soddu S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):135. PubMed ID: 27599564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.
    Prodosmo A; De Amicis A; Nisticò C; Gabriele M; Di Rocco G; Monteonofrio L; Piane M; Cundari E; Chessa L; Soddu S
    J Clin Invest; 2013 Mar; 123(3):1335-42. PubMed ID: 23454770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
    Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK
    Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
    Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
    Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
    Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological features of breast cancer in carriers of ATM gene variants.
    Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
    Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients.
    Sierra-Díaz DC; Morel A; Fonseca-Mendoza DJ; Bravo NC; Molano-Gonzalez N; Borras M; Munevar I; Lema M; Idrobo H; Trujillo D; Serrano N; Orduz AI; Lopera D; González J; Rojas G; Londono-De Los Ríos P; Manneh R; Cabrera R; Rubiano W; de la Peña J; Quintero MC; Mantilla W; Restrepo CM
    Hum Genomics; 2024 Jun; 18(1):68. PubMed ID: 38890714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
    Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J
    Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
    Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
    BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
    Osorio A; Pollán M; Pita G; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Preisler-Adams S; Niederacher D; Hofmann W; Gadzicki D; Jakubowska A; Hamann U; Lubinski J; Toloczko-Grabarek A; Cybulski C; Debniak T; Llort G; Yannoukakos D; Díez O; Peissel B; Peterlongo P; Radice P; Heikkinen T; Nevanlinna H; Mai PL; Loud JT; McGuffog L; Antoniou AC; Benitez J;
    Br J Cancer; 2008 Sep; 99(6):974-7. PubMed ID: 18781154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
    Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
    Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
    Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
    Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
    DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
    Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.